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Surnrnary. Crohn's disease (CD) is a chronic 
inflammatory intestinal disorder with disturbance and 
injury of the intestinal mucosal barrier, in which various 
proinflammatory molecules as well as molecules with 
antiinflammatory activity and cytoprotective function 
are found to be expressed. We investigated whether 
clusterin, a multifunctional cytoprotective protein, is 
upregulated in Crohn's disease, because augmented 
expression of clusterin is seen in many organs following 
various forms of tissue injury. Human actively and 
inactively inflamed ileal tissues from CD patients as well 
as normal intestinal specimens from control patients 
(normal ileum) were investigated by Western blot 
analysis, immunohistochemisty and in situ hybridization. 
As compared with controls, a strongly enhanced 
expression of clusterin was found in CD tissues, 
correlating with disease activity. Immunohistochemistry 
and in situ hybridization analysis revealed foci of crypts 
almost completely lined by clusterin expressing 
enterocytes in CD, a feature that was never seen in 
controls. Such crypts appeared especially within the 
morphologically intact mucosa apart from erosive or 
ulcerative lesions. Besides epithelia, clusterin was also 
expressed by inflammatory mononuclear cells. Enhanced 
expression of clusterin by crypt epithelia might reflect a 
cytoprotective function of the protein in order to prevent 
further injury of the intestinal mucosal barrier in CD. 
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lntroduction 
Crohn's disease (CD) is associated with increased 
permeability of the intestinal mucosal barrier (Olaison et 
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al. ,  1990; Hollander, 1992; Peeters et al., 1994). 
Evidence is given that permeability changes in CD are 
related to disease activity (Pironi et al., 1990; Wyatt et 
al., 1993). In relatives of patients with CD, deranged 
intestinal permeability has been reported, pointing to the 
possibility of a hereditary defect in barrier function 
(Hollander et al., 1986; May et al., 1993; Hilsden et al., 
1996; Soderholm et al., 1999a). In experimental animal 
models, bypassing (Yamada et al., 1993; Fries et al., 
1999) or breaching (Hermiston and Gordon, 1995) the 
epithelial barrier can initiate disorders similar to CD. 
These data suggest that a defect in the intestinal barrier 
could be of etiological importance in CD (Soderholm et 
al., 1999b). On the other hand, it has been shown that 
molecules with cytoprotective function, such as activin, 
are upregulated at sites of inflammatory tissue damage 
(Hübner et al., 1999). 
Clusterin - first described in 1983 as a major 
secretory glycoprotein produced by ram Sertoli cells 
(Blaschuk et al., 1983) - is physiologically expressed in 
a wide variety of tissues and shows a high degree of 
sequence consewation between species (for review see 
Rosenberg and Silkensen, 1995). Various functions for 
clusterin have been described, including induction of 
cellular aggregation (Silkensen et al., 1995), regulation 
of apoptosis (Buttyan et al. ,  1989), membrane 
remodeling (Fritz and Murphy, 1993), inhibition of 
complement function (Jenne and Tschopp, 1989), and 
modulation of fluid-tissue interfaces (Jordan-Starck et 
al., 1992). Moreover, augmented clusterin expression 
has been found in a variety of disease states and local 
overexpression of clusterin has been seen in tissue 
injuries (Silkensen et al., 1994), such as local acidosis, 
androgen ablation of the prostate gland, and diverse 
kidney diseases (summarized and cited in Rosenberg and 
Silkensen, 1995). Recently, it has been shown that 
clusterin has a cytoprotective function at sites of tissue 
damage through i ts  genuine ability to prevent 
inappropriate precipitation of secreted or cell-surface 
proteins in a chaperone-like manner (Humphreys et al., 
1999; Hochgrebe et al., 2000; Wilson and Easterbrook- 
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Smith, 2000). Experimental data indicate that pH 
induced changes in the molecular structure of clusterin 
are responsible for its enhanced ability to bind ligands at 
mildly acidic pH (Hochgrebe et al., 2000; Wilson and 
Easterbrook-Smith, 2000). At sites of inflammation or 
tissue damage the local pH can drop to below 6, a 
phenomenon described as local acidosis (Hochgrebe et 
al., 2000; Wilson and Easterbrook-Smith, 2000). Such a 
state of local acidosis is likely to occur in inflamed gut 
in CD. 
The expression of clusterin in the terminal ileum, a 
preferential site of CD in humans, has not been studied 
yet. The aim of the present work was to assess the 
expression of clusterin on the protein and on the mRNA 
leve1 in ileal tissues of CD patients. 
Materiais and methods 
Patients and tissues 
Surgical resection of the ileocaecal region including 
the terminal ileum was performed in 10 patients with CD 
(mean age, 37 years; range, 22 to 59 years) and in 10 
patients (mean age, 58 years; range, 39 to 69 years) with 
sporadic cancer of the ascending colon. The non affected 
terminal ileum of the 10 patients with sporadic cancer 
served as normal controls. In patients with CD, surgical 
resection was necessary due to stenosis of the intestinal 
segment and resistance to medical therapy (including 
corticosteroids in 6 patients; mesalazine in 5 patients). 
Diagnosis of CD was established by conventional 
clinical and histological criteria. Al1 surgical specimens 
were opened longitudinally along the antimesenteric 
border. For subsequent analysis, samples of about 1 cm2 
in size were taken. One half of the unfixed material was 
used for molecular experiments (see below), the other 
half was postfixed in formaldehyde, subsequently 
paraffin embedded and used for morphological and 
immunohistological analysis. 
Grading of inflammation 
H&E-stained sections from paraffin-embedded 
tissues were used to define the inflammatory degree of 
CD tissues: the term 'inactive inflammation' (1) was 
used when the amount of lymphocytes and plasma cells 
in the stroma was increased (n=4) as compared with 
controls. 'Active inflammation' (A) designates intestinal 
CD tissues (n=6) where destructive lesions such as 
granulocytes, cryptitis, crypt abscesses, erosive defects 
andlor ulcers were additionally seen. 
Preparation of riboprobes and in situ hybridization 
A 1.36 kbp rat clusterin cDNA fragment subcloned 
in pBluescript SK- [a kind gift  from R. Buttyan, 
(Buttyan et al., 1989)], was used to prepare digoxigenin- 
labeled sense and antisense riboprobes. The identity and 
the orientation of the insert was verified by sequencing. 
For generation of the antisense probe plasmid was 
linearized with Bam H1 and transcribed with T7 RNA 
polymerase; for generation of the sense probe, plasmid 
was linearized with Hind 111 and transcribed with T3 
RNA polymerase. Because clusterin shows a high degree 
of conservation among species, a rat cDNA could be 
used for studies on human tissues. We have previously 
used the same cDNA to detect clusterin mRNA 
expression in rat polycystic kidneys (Obermüller et al., 
1997). In vitro transcription was carried out using a 
commercially available kit (Roche Diagnostics,  
Mannheim Germany) according to the manufacturer's 
suggested protocol. To improve the penetration of the 
probes during the in situ hybridization experiments, the 
transcripts were shortened to a calculated average length 
of 250 bases by alkaline hydrolysis. 
In situ hybridization was carried out on tissues of 
three randomly-selected CD-patients (n=3) and controls 
(n=3), as described previously, with slight modifications 
(Obermüller et al., 1998). In brief, deparaffinized 
sections were postfixed in 4% paraformaldehyde1PBS 
for 10 min, rinsed three times in PBS and then treated 
with proteinase K (8 pglml in PBS) for 30 min at 37 "C. 
Thereafter sections were washed briefly in PBS and 
fixed again for 1 minute in 4% paraformaldehydePBS 
and washed. To reduce background, slides were 
acetylated for 15 minutes in 0.1M triethanolamine, pH 
8.0, containing 0.25% acetic anhydride, added 
immediately before starting this step. After rinsing in 
PBS slides were dehydrated in 70, 80, and 95% ethanol 
and air-dried. 
Prehybridization and hybridization as well as the 
immunological detection of the hybridized riboprobes 
were performed as described previously (Obermüller et 
al., 1998). Hybridization was carried out overnight at a 
temperature of 46 "C; the hydrolysed clusterin probe was 
used at a concentration of 2 to 4 ng per p l  hybridization 
mixture. Control experiments included incubations with 
sense probes on alternate sections. In addition, other 
sections were hybridzed without antisense probe or by 
omitting the anti-digoxigenin antibody. Al1 controls 
yielded completely negative results. 
Antibodies and immunohistochemistry 
For immunohistological staining experiments (IH) 
and immunoblotting analyses (IB) the following primary 
and secondary antibodies, diluted as  indicated in 
brackets, were used: goat polyclonal anti-clusterin 
antibody (IH, 4 pglml; IB, 0.4 pglrnl); mouse anti-B- 
actin antibody (IB, 0.2 pglml); and horse-radish- 
peroxidase (HRP) conjugated affinity-purified anti-goat 
as  well as  anti-mouse antibodies (IB, 1:5000); al1 
antibodies were purchased from Santa Cruz 
Biotechnology, Inc., Santa Cruz, USA. The biotin- 
coupled sheep anti-goat antibody (IH, 1:200) was 
purchased from Dianova, Hamburg, Germany. For ABC 
immunostaining, an ABC detection kit with DAB as the 
chromogen (DAKO, Hamburg, Germany) was used in 
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accordance to the manufacturer7s suggested protocols. 
Finally, immunostained sections were counterstained 
with hematoxylin and mounted. Immunohistochemistry 
was carried out on tissues of al1 CD-patients (n=10) and 
controls (n=10). 
Preparation of tissues, SDS-PAGE, and Western blot 
analysis: Specimens of the terminal ileum (about 300 
mg) of five randomly-selected CD-patients (n=5) and 
controls (n=5) were homogenized in 10 mM Tris-HCl, 
pH 7.4 containing 10% glycerol using the Ultra Turrax 
equipment (IKA Labortechnik, Staufen, Germany) in an 
ice bath with a tissue to buffer ratio of 1:3.  The  
homogenates were centrifuged at x42,OOOg at 4 OC for 
one hour. The supernatants in reducing Laemmli buffer 
were subsequently used in Western blot analysis. This 
procedure was adapted from the method of Grima et al. 
(1990). Protein measurements were performed using the 
BioRad assay reagent (BioRad, München, Germany). 
Samples were stored at -20 OC until use. 
One-dimensional SDS-PAGE (10%) was performed 
according to the method of Laemmli (Laemmli, 1970). 
Molecular weight markers were purchased from 
Amersham (Amersham International plc, Little Chalfont, 
UK). 15 p g  of total protein were loaded for each sample, 
separated under reducing and denaturing conditions and 
transferred to a PVDF Immobilon-P membrane 
(Millipore Corporation, Bedford, MA, USA) using a 
semi-dry blot equipment. The ECL substrate (Amersham 
International plc, Little Chalfont, UK) was applied for 
subsequent detection. For antibody stripping, blots were 
immersed in methanol, washed in water and incubated in 
stripping buffer consisting of 2% SDS, 100 mM B- 
mercaptoethanol, and 62.5 mM Tris-HC1 (pH7.5) for 30 
min at 50 "C. Subsequently, blots were processed as 
described above in order to evaluate B-actin as loading 
control. Negative controls included blotting experiments 
in which the primary antibody was omitted. 
Results 
The expression of immunoreactive clusterin was 
increased in tissue homogenates of the terminal ileum of 
CD patients when compared with the normal controls 
(non affected terminal ileum of 5 randomly selected 
patients with sporadic cancer). Two bands specific for 
clusterin were detected at a molecular mass of about 40 
kDa, which is in agreement with the reported molecular 
mass of the alpha and beta chains of human clusterin 
(Murphy et al., 1988). In CD, expression of clusterin 
was strongly increased in actively inflamed tissues of the 
terminal ileum as compared with inactively inflamed 
ileal specimens (moderate increase) or in control ileal 
tissues (Fig. 1). Thus, the amount of immunoreactive 
clusterin in ileal samples paralleled the severity of the 
inflammatory bowel disease. 
Using immunohistochemistry in CD and control 
tissues (non affected terminal ileum of the 10 patients 
with sporadic cancer), expression of clusterin was found 
in individual enterocytes of the apical villus as well as in 
intestinal lymphatic follicles (Figs. 2, 3A). Interestingly, 
in CD clusterin was additionally expressed by 
enterocytes lining crypts, a phenomenon clearly different 
from that seen in normal controls (Fig. 3). Exclusively in . 
CD, foci of crypts almost completely lined by clusterin 
expressing enterocytes were found, as seen in the 
overview in figure 3A. Although in many cases clusterin 
protein expressing enterocytes intermingled with 
unreactive epithelial cells, occasionally, various crypts 
were almost completely lined with immunostained 
epithelial cells (Fig. 3B). Notably, histomorphological 
signs of apoptosis were not encountered in these cells. 
At sites of erosive defects or ulcers, the epithelium of 
very few crypts occasionally showed immunostaining 
for clusterin, but the overwhelming number of crypts 
was devoid of specific detection signals. Also in the 
surface epithelium bordering such mucosa1 defects, 
immunostained epithelial cells were regularly lacking 
(Fig. 3C). In CD, clusterin was also strongly expressed 
by inflammatory cells within the lamina propria (e.g., 
granulocytes, lymphocytes) and by lymphocytes of 
intestinal lymphatic follicles (Fig. 3A). Inflammatory 
cells at sites of erosive defects and ulcers were regularly 
positive for clusterin (Fig. 3C). However, 
immunoreactivity of clusterin expressed in leucocytes 
showed interindividual differences. In the majority of 
CD tissues (n=7), expression of clusterin in leukocytes 
was strong. In the other CD tissues (n=3),  the 
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Fig. 1. Western blot analysis of clusterin protein expression in actively 
(A) and inactively (1) inflamed ileal tissues of Crohn's disease and in 
unaffected ileal tissues of controls (C): Clusterin expression is increased 
in Crohn's disease (A and 1) in comparison to normal controls. B-actin 
labeling and a Coomassie-stained PVDF membrane are shown as 
loading controls. 
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lymphocytes exhibited only a moderate staining, 
whereas no expression was seen in granulocytes. 
The findings obtained by immunohistochemistry 
were corroborated by the results of the in  situ 
hybridization experiments performed on CD tissues. The 
overview in figure 4A shows a strong expression of 
clusterin mRNA by epithelial cells, preferrably located 
in crypts, but also in some cells of the apical part of the 
villi. In addition, clusterin mRNA was found to be 
expressed by inflammatory cells present in the villous 
stroma and in cells of lymphatic follicles (Figs. 4A,B). 
The detailed analysis in figure 4C shows that especially 
epithelial cells lining crypts exhibited a strong 
expression of clusterin mRNA. 
Discussion 
CD is a chronic inflammatory bowel disease 
histologically characterized by segrnental and transmural 
inflammation. The intestinal segment most commonly 
involved in CD is the terminal ileum, but al1 sites of the 
gastrointestinal tract may be affected discontinuously 
(Desreumaux et al., 1999). One interesting hypothesis 
assumes a primary defect in the intestinal barrier 
(Soderholm et al., 1999b), because increased intestinal 
permeability has been found in CD patients (Olaison et 
al., 1990; Hollander, 1992; Peeters et al., 1994) and in 
their relatives (Hollander et al., 1986; Hilsden et al., 
1996; Soderholm et al., 1999a). 
Clusterin is a multifunctional protein showing a 
wide physiological tissue distribution as well as a 
marked induction in a variety of states of tissue injury 
and remodeling (for review see Rosenberg and 
Silkensen, 1995). Arnple evidence suggests that clusterin 
exerts cytoprotective functions, although the expression 
of this protein under different pathophysiological 
conditions still remains puzzling. 
Our data reveal that the expression of clusterin is 
upregulated in the small intestine of CD patients in 
comparison to ileal control tissues. The data obtained by 
Western blot analysis show that the amount of the 
clusterin protein expressed correlated with disease 
Flg. 2. lmmonohistochernical detecüon oi cimterin using the ABC technique in unaffected control tissue of the terminal ileum. A. llsal mucosa with 
elender and ghart vill lined by cokKnnar epittiellal alla rind goblet d l s .  At the apical tip few enterocytes are axprdng dusterln. B. High magnifioaüon 
oi tile surface epitM1um in the vldnity of a lyniphold foilicle. l3pf888ion of ciustgrin is found within the fbllicle and in single epithelial cells oi the surface 
epithelium. A, x 80; B, x 250 
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activity. The fact that clusterin is also detectable in tissue 
homogenates of control samples demonstrates that 
different cells in the normal intestine also produce 
clusterin at probably low levels. Previous reports 
demonstrated expression of clusterin in the small 
intestine of rat and mouse (Aganval et al., 1996; Arai et 
al., 1996) pointing to a role in tissue differentiation and 
remodelling (Ahuja et al., 1994). Likewise, in the human 
terminal ileum clusterin might be secreted during the 
normal differentiation of e.g. enterocytes. It must also be 
considered that a variable small number of mononuclear 
cells present in the intestine as well as clusterin-positive 
cells from lymphatic follicles may contribute to the 
overall clusterin expression seen in controls of the 
western blot analysis. 
Our results are in good agreement with other recent 
experimental data showing that clusterin is expressed at 
sites of active inflammation and tissue damage 
(Hochgrebe et al., 2000; Wilson and Easterbrook-Smith, 
2000). In the diseased ileal tissues investigated by 
immuno-histochemistry, expression of clusterin was seen 
in epithelial cells on the one hand and inflammatory 
cells on the other hand. The high number of 
inflammatory cells expressing clusterin mRNA may 
largely account for high amounts of clusterin seen in the 
Western blot analysis. However, the particular 
expression of clusterin by enterocytes of crypts was a 
unique and prominent feature detected exclusively 
within CD tissues. Of note, when estimating the amount 
of clusterin mRNA expression by the time-dependent 
appearance of the hybridization signal during colour 
development, is that the strongest signals were obtained 
Flg. 3. lmmunohistochemical detection of clusterin using the ABC technique in actively (A, C) and inactively (B) inflamed ileal tissues with Crohn's 
disease. A. In the ovewiew, expression of immunoreactive clusterin can be seen in epithelial as well as in inflammatory cells (actively iníiamed tissue). 
Strong immunoreactivity for clusterin is apparent in strings of epithelial cells located in crypts. B. Clusterin protein expressing enterocytes intermingled 
with unreactive epithelial cells are also existent in inactively inflamed Crohn's disease. C. Act i i ly inflamed ileal tissue with a large ulcerative lesion 
(right upper corner). Only few crypts adjacent to the ulcerative injury are immunostained. Note that the surface epithelium is without any staining. 
Several inflammatory cells in the stroma are immunostained for clusterin. A, x 30; B, x 240; C, x 150 
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in epithelial cells of crypts before the appearance of the 
signal in other cell types. This raises some interesting 
questions about the role of clusterin especially in those 
locations. We have previously shown in a rat model of 
polycystic kidney disease, that clusterin mRNA is 
strongly upregulated in distinct renal epithelial cells, also 
including cystic epithelia. This prompted us to speculate 
that clusterin serves to maintain cell integrity, therefore 
being protective rather than being a mediator of cell 
injury (Obermüller et al., 1997). Thus, it is possible that 
clusterin might promote cell-cell interactions which are 
perturbated in the setting of CD. Whether this is in 
response to primary or secondary events in CD must 
remain speculative. 
Interestingly, increased clusterin expression was not 
an evident feature of cells in the vicinity of erosive and 
ulcerative lesions. It is possible that clusterin is induced 
much more earlier in  enterocytes, that is, before 
ulcerative lesions have been formed. Clusterin 
expression in crypts may therefore indicate an early type 
of epithelial injury. Notably, CD is associated with an 
increased intestinal permeability (Hollander, 1992), 
indicating disturbance of the intestinal barrier including 
defects of the epithelial cellular layer. Therefore 
upregulated clusterin may function to protect cell 
membranes as has been recently suggested (Rosenberg 
and Silkensen, 1995). 
Finally, it cannot be excluded that e.g. a persistent 
disturbance in differentiation of enterocytes leads to 
increased clusterin production, since it is well known 
that this protein is induced spatially and temporarly 
during organogenesis and differentiation of cells (French 
et al., 1993). Moreover, a previous study demonstrated 
upregulated expression of clusterin mRNA in the small 
FQ 4. In situ hybridiration for ckreterin mRNA uslng dlgoxigmln-labeled riboprobes in adively (A, 8) and inacüvely (C) infiamd ¡leal üSsues with 
6rohn's diaeese. A. In the wentiew, datwin mRNA ~xpresslon is wen in gcpt epMteHum and in iníiammatoiy stromal celb. B and C. Detailed views 
of dwtwin mRNA expreseion in wypb; (B) L a  Mgher mqniflaetlwi of (A); (C) shws the expmdon ppat tem in an tnacth/ely fnff- specimen. Note 
the dwterin mRUA expressing lymphatic falllde ln the lefi kmer comer of (B). 4 x 30, B, x 50: C, x 240 
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and the large intestine of the rat after irradiation (Arai et 
al., 1996). That investigation showed a temporal link 
between apoptosis and clusterin expression in 
enterocytes. In our study, however, we did not find 
histomorphological characteristics of apoptosis in 
clusterin-positive epithelial cells, which were located at 
the basis of mucosal crypts, whereas apoptotic 
enterocytes are typically seen at the most apical parts of 
the mucosal villi, as demonstrated recently (Arai et al., 
1996). Future studies will have to address whether the 
sites of clusterin expression in CD are associated with 
abnormalities of epithelial differentiation. 
In summary, we found that the expression of 
clusterin in CD of the terminal ileum is upregulated as 
compared with normal controls. The protein was 
basically expressed by enterocytes and inflammatory 
mononuclear cells. Foci of crypts almost completely 
lined by clusterin expressing enterocytes were 
exclusively found in CD tissues, but never seen in 
controls. Such crypts appeared especially within the 
morphologically intact mucosa apart from erosive or 
ulcerative lesions. Increased expression of clusterin by 
crypt enterocytes might reflect a cytoprotective function 
of the protein in order to prevent further disturbances of 
the intestinal mucosal barrier in CD. 
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